Back to Authors

Moreau, Philippe

https://orcid.org/0000-0003-1780-8746

Mayo Clinic

Centre Hospitalier Universitaire de Nantes

Citations 126

Phase I interim safety and efficacy of venetoclax (ABT-199/GDC-0199) monotherapy for relapsed/refractory (R/R) multiple myeloma (MM).
Kumar, Shaji , Vij, Ravi , Alzate, Stefanie, Morris, Lura, Dunbar, Martin, Zhu, Ming , Enschede, Sari H., Humerickhouse, Rod, Kaufman, Jonathan L. , Mıkhael, Joseph , Facon, Thierry T.F. , Moreau, Philippe , Amiot, Martine , Ross, Jeremy A. , Agarwal, Suresh K, Leverson, Joel D. , Touzeau, Cyrille

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8576-8576

10.1200/jco.2015.33.15_suppl.8576 Get It

Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an interim analysis of the phase III study ASPIRE (NCT01080391)
Stewart, A. Keith, Mihaylov, Georgi , Rajnics, Péter , Suvorov, Aleksandr , Niesvizky, Rubén, Zojwalla, Naseem J., Palumbo, Antonio , Dimopoulos, Meletios Α. , Stewart, A. Keith, Rajkumar, S. Vincent , Masszi, Tamás , Oriol, Albert , Hájek, Roman , Rosiñol, Laura , Siegel, David S. , Goranova-Marinova, Vesselina S , Jakubowiak, Andrzej , Miguel, Jesús F. San , Ludwig, Heinz , Moreau, Philippe

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8525-8525

10.1200/jco.2015.33.15_suppl.8525 Get It

FIRST study: Updated overall survival (OS) in stem cell transplant (SCT)-ineligible newly diagnosed multiple myeloma (NDMM) patients (pts) treated with continuous lenalidomide plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)
Hulin, Cyrille , Belch, Andrew R. , Reece, Donna , Catalano, John, Qiu, Lugui , Schots, Rik , Marek, Jennifer, Chen, Guang , Ervin‐Haynes, Annette, Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Pinto, Antonio , Ludwig, Heinz , Bahlis, Nizar Jacques , Cavo, Michèle , Moreau, Philippe , Qiu, Lugui , LeBlanc, Richard , Rajkumar, S. Vincent

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 8524-8524

10.1200/jco.2015.33.15_suppl.8524 Get It

Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.
Kumar, Shaji , Vij, Ravi , Pegourié, Brigitte, Benboubker, Lotfi , Gasparetto, Cristina, Diehl, Susan, Alzate, Stefanie, Dunbar, Martin, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Kaufman, Jonathan L. , Mıkhael, Joseph , Facon, Thierry T.F. , Gasparetto, Cristina , Amiot, Martine , Moreau, Philippe , Ross, Jeremy A. , Agarwal, Suresh K, Leverson, Joel D. , Touzeau, Cyrille

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8032-8032

10.1200/jco.2016.34.15_suppl.8032 Get It

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
Richardson, Paul G. , Palumbo, Antonio , Viterbo, Luísa, Nagler, Arnon , Yehuda, Dina Ben , Pour, Luděk, Langer, Christian , Pluta, Andrzej, Berg, Deborah, Velde, Helgi van de , Esseltine, Dixie-Lee, Bacco, Alessandra Di , Richardson, Paul Gerard Guy , Avet‐Loiseau, Hervé , Ganly, Peter S. , Miguel, Jesús F. San , Rajkumar, S. Vincent , Bahlis, Nizar Jacques , Masszi, Tamás , Lin, Jianchang , Esseltine, Dixie‐Lee, Moreau, Philippe

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8018-8018

10.1200/jco.2016.34.15_suppl.8018 Get It

Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Chanan‐Khan, Asher , Agarwal, Amit , Kumar, Shaji , Diehl, Susan, Cordero, Jaclyn, Munasinghe, Wijith, Zhu, Ming , Maciag, Paulo , Verdugo, Maria E., Moreau, Philippe , Roberts, Andrew W. , Facon, Thierry T.F. , Touzeau, Cyrille , Ross, Jeremy A. , Salem, Ahmed Hamed , Leverson, Joel D. , Harrison, Simon J

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8011-8011

10.1200/jco.2016.34.15_suppl.8011 Get It

Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM).
Risse, Marie‐Laure , Asset, Gaëlle, Martin, Thomas G. , Dimopoulos, Meletios Α. , Yong, Kwee , Mıkhael, Joseph , Moreau, Philippe

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS8060-TPS8060

10.1200/jco.2018.36.15_suppl.tps8060 Get It

Once-weekly vs twice-weekly carfilzomib (K) dosing plus dexamethasone (d) in patients with relapsed and refractory multiple myeloma (RRMM): Results of the randomized phase 3 study A.R.R.O.W.
Mateos, María‐Victoria , Lazzaro, Antonio, Song, Kevin , Huang, Mei , Zahlten‐Kumeli, Anita, Stewart, A. Keith, Moreau, Philippe , Berenson, James R. , Weisel, Katja C , Dimopoulos, Meletios Α.

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 8000-8000

10.1200/jco.2018.36.15_suppl.8000 Get It

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
Walker, Brian A. , Mavrommatis, Konstantinos , Wardell, Christopher P. , Ashby, Cody , Bauer, Michael , Davies, Faith E. , Hoering, Antje , Samur, Mehmet , Towfic, Fadi , Flynt, Erin , Yu, Zhinuan, Yang, Zhihong, Rozelle, Dan , Obenauer, John C. , Trotter, Matthew , Auclair, Daniel , Keats, Jonathan J. , Bolli, Niccolò , Fulciniti, Mariateresa , Szalat, Raphaël , Moreau, Philippe , Durie, Brian G.M. , Stewart, A. Keith, Goldschmidt, Hartmut , Sonneveld, Pieter , Miguel, Jesús F. San , Jackson, Graham , Avet‐Loiseau, Hervé , Munshi, Nikhil , Thakurta, Anjan , Morgan, Gareth J. , Moreau, Philippe , Bolli, Niccolo' , San-Miguel, Jesus , Davies, Faith E , Keats, Jonathan J , Walker, Brian A , Morgan, Gareth J , Rosenthal, Adam , Wang, Hongwei , Qu, Pingping , Ortiz, María , Raab, Marc S. , Einsele, Hermann , Lonial, Sagar , Anderson, Kenneth C. , Flynt, Erin , Samur, Mehmet K , Szalat, Raphael

Blood | June 8, 2018 | Volume: 132 | Issue: 6 | Pages: 587-597

10.1182/blood-2018-03-840132 Get It

Key Points Using the largest set of patients with newly diagnosed myeloma, we identified 63 mutated driver genes. We identified oncogenic dependencies, particularly relating to primary translocations, indicating a nonrandom accumulation of genetic hits.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Catalano, John, Belch, Andrew , Cavo, Michèle , Pinto, Antonello, Banos, Anne , Tiab, Mourad, Delforge, Michel , Cavenagh, Jamie, Lee, Je‐Jung , Chen, Christine , Oriol, Albert , Rubia, Javier de la , White, Darrell , Binder, Daniel, Moreau, Philippe , Perrot, Aurore , Arnulf, Bertrand , Qiu, Lugui , Roussel, Murielle , Boyle, Eileen M. , Manier, Salomon , Mohty, Mohamad , Avet‐Loiseau, Hervé , Leleu, Xavier , Ervin‐Haynes, Annette, Chen, Guang , Houck, Vanessa, Benboubker, Lotfi , Hulin, Cyrille , Pinto, Antonio , Moreau, Philippe , Perrot, Aurore , Boyle, Eileen M , Facon, Thierry T.F. , Dimopoulos, Meletios Α. , Dispenzieri, Angela , Pinto, Antonello, Weisel, Katja C , Ludwig, Heinz , Bahlis, Nizar Jacques , Geraldes, Catarina , Lu, Jin Ping , Anderson, Kenneth C. , Attal, Michel , Qiu, Lugui , Roussel, Murielle , Pinto, Antonio , Oriol, Albert , Mohty, Mohamad

Blood | November 17, 2017 | Volume: 131 | Issue: 3 | Pages: 301-310

10.1182/blood-2017-07-795047 Get It

Key Points Rd continuous significantly extended OS compared with MPT and resulted in comparable OS to that with Rd18 in patients with multiple myeloma. Patients achieving complete or very good partial response with Rd benefited greatly from continuous vs fixed treatment in terms of PFS.